An independent Centers for Disease Control and Prevention advisory committee voted unanimously Thursday evening to recommend booster shots for both the Moderna and Johnson & Johnson COVID-19 vaccines for certain populations.

The panel recommended a third dose of the Moderna vaccine at least six months after a person’s initial course for those 65 and older, as well as those as young as 18 who are at higher risk due to underlying health conditions or where they work or live.

A second dose of the one-shot Johnson & Johnson vaccine was recommended for anyone aged 18 and older, at least two months after the first dose.

The panel also cleared the way for allowing mixing and matching of booster doses.

The recommendations fall in line with the Food and Drug Administration’s authorization of the boosters Wednesday.

CDC Director Rochelle Walensky must now sign off on the panel's recommendations. A decision is expected within a day.

-ABC News' Sasha Pezenik

COVID-19 hospital admissions in the U.S. have dropped by about 9.7% in the last week, according to federal data.

Death rates are also falling, though they remain persistently high, with an average of just under 1,250 Americans dying from the virus each day, according to the data.

Alaska currently has the country's highest infection rate, followed by Montana, Wyoming, Idaho and North Dakota.

The U.S. is currently averaging around 76,000 new cases per day, down from 160,000 in early September. Despite boasting high vaccination rates, several Northern states continue to see cases tick up as the weather gets colder.

-ABC News' Arielle Mitropoulos

The U.S. vaccination initiation average is at one of its lowest points since the introduction of vaccines nearly 10 months ago, according to federal data. Just over 182,000 Americans are receiving their first dose each day, while roughly 335,000 Americans are receiving a booster shot each day.

More than 112.5 million Americans remain unvaccinated and about 64.3 million of the unvaccinated are over the age of 12, and thus currently eligible for a shot, according to federal data. 

The FDA authorized boosters for Moderna and J&J late Wednesday. The Moderna booster is authorized for adults 65 and older and those at high-risk. The J&J booster is authorized for adults at least two months after their primary vaccination.

The FDA said it's OK to mix a booster but did not say any booster combination was preferred over another.

-ABC News' Sony Salzman, Arielle Mitropoulos

A CDC committee is meeting Thursday to discuss and vote on booster shots for the Moderna and Johnson & Johnson vaccines, as well as if people can mix and match their booster doses.

On Wednesday evening, the FDA authorized Moderna and J&J boosters for some people and allowed for the mixing and matching booster doses.

The next step of the process is for the CDC panel to deliberate and ultimately vote on whether to recommend those boosters, and whether to allow mixing and matching. The CDC panel vote is expected around 4:30 p.m.

After the panel vote, CDC Director Rochelle Walensky will make the final decision, likely within one day. The panel's vote is nonbinding and the CDC is not required to follow the panel's recommendations.

Boosting for eligible Moderna and J&J recipients would be able to start once Walensky gives the greenlight.

The FDA has made it clear that there is no preferred booster vaccine for the mixed dosage, but the CDC panel on Thursday is likely to discuss available data on what booster blend might offer the strongest immunity.

-ABC News' Sasha Pezenik

The Pfizer COVID-19 vaccine is nearly 91% effective against symptomatic illness in children ages 5-11, according to new data posted Friday ahead of a major FDA advisory committee meeting on Tuesday.

The vaccine also appeared safe, with none of the children experiencing a rare heart inflammation side effect known as myocarditis. If authorized in children 5-11, the Pfizer vaccine will be given at a smaller, one-third dose.

This efficacy estimate is from the company's clinical trial of 2,268 children in which some children got a placebo, and some children got the Pfizer vaccine. During the trial, 16 children who got the placebo shots developed COVID-19. Only three children who got the real vaccine developed COVID-19.

A small number of the children who were vaccinated and later developed COVID-19 experienced symptoms far fewer and milder than the children who were unvaccinated. For example, none of the vaccinated children developed a fever, while a majority of the unvaccinated children developed a fever along with other symptoms.

None of the children experienced serious adverse events. Many experienced typical symptoms like pain at the injection site, fatigue and headache.

The FDA's advisers will meet Tuesday to vote on whether to authorize the vaccine. From there, the FDA itself and the CDC will need to sign off -- a process that can take several days -- before shots could become available to children nationally.

- ABC News' Sony Salzman